C_Clayton_Jones
Diamond Member
‘The Trump administration has approved a new generic version of the mifepristone abortion pill, a decision made quietly by the Food and Drug Administration this week that is now prompting uproar among antiabortion leaders.
The administration’s approval of the drug on Tuesday comes less than two weeks after Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Martin Makary said the department was conducting a review of the safety of abortion pills, a decision that antiabortion activists welcomed.
Now, those same leaders are questioning the administration’s commitment to their cause, marking the first significant pushback Trump has received from his otherwise loyal base of socially conservative activists. “This is a wildly disappointing decision. We are extraordinarily disappointed,” said Kristi Hamrick, vice president of media and policy for Students for Life of America, in an interview with The Washington Post. “This has to be addressed.”
Hamrick referred to the FDA’s decision as “the opposite of the gold standard review” that antiabortion leaders believed the Trump administration was conducting into mifepristone, and is among the activists questioning why FDA would green-light the approval before launching the safety study.’
Unfortunately the right isn’t infuriated with millions of Americans losing access to affordable healthcare.
Instead they get infuriated with women exercising their right to reproductive autonomy in free states where that right is acknowledged and respected.
The administration’s approval of the drug on Tuesday comes less than two weeks after Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Martin Makary said the department was conducting a review of the safety of abortion pills, a decision that antiabortion activists welcomed.
Now, those same leaders are questioning the administration’s commitment to their cause, marking the first significant pushback Trump has received from his otherwise loyal base of socially conservative activists. “This is a wildly disappointing decision. We are extraordinarily disappointed,” said Kristi Hamrick, vice president of media and policy for Students for Life of America, in an interview with The Washington Post. “This has to be addressed.”
Hamrick referred to the FDA’s decision as “the opposite of the gold standard review” that antiabortion leaders believed the Trump administration was conducting into mifepristone, and is among the activists questioning why FDA would green-light the approval before launching the safety study.’
Unfortunately the right isn’t infuriated with millions of Americans losing access to affordable healthcare.
Instead they get infuriated with women exercising their right to reproductive autonomy in free states where that right is acknowledged and respected.
